New UK Cost-Effectiveness Thresholds ‘Modest’ In Nature, Will Not Benefit All Drugs

 
• By Eliza Slawther
  
The UK has fallen in attractiveness for drug launches in recent years, a lawyer says (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Health Technology Assessment

More from United Kingdom